Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 63697
1. Lapčević M, Vuković M, Gvozdenović BS, Mioljević V, Marjanović S: Socioeconomic and therapy factor influence on self-reported fatigue, anxiety and depression in rheumatoid arthritis patients. Rev Bras Reumatol; 2017 Feb 27;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic and therapy factor influence on self-reported fatigue, anxiety and depression in rheumatoid arthritis patients.
  • [Transliterated title] Influência de fatores socioeconômicos e de tratamento sobre a fadiga, ansiedade e depressão autorrelatadas em pacientes com artrite reumatoide.
  • INTRODUCTION: Fatigue, anxiety and depression are very frequent symptoms in patients with rheumatoid arthritis (RA).
  • Self-reported patients health status was measured by: Fatigue Assessment Scale, Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7.
  • 1) non-steroidal anti-inflammatory drugs (NSAIDs) and/or analgesics and/or corticosteroids;.
  • 2) synthetic disease-modifying antirheumatic drugs (DMARDs) alone or in combination with corticosteroids and/or NSAIDs and 3) any RA treatment which includes biologic DMARDs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Editora Ltda.
  • (PMID = 28336154.001).
  • [ISSN] 1809-4570
  • [Journal-full-title] Revista brasileira de reumatologia
  • [ISO-abbreviation] Rev Bras Reumatol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Keywords] NOTNLM ; Ansiedade / Anxiety / Artrite reumatoide / Depression / Depressão / Fadiga / Fatigue / Rheumatoid arthritis / Therapy / Tratamento
  •  go-up   go-down


2. Lee JI, Kim IH, Nam TJ: Crude extract and solvent fractions of Calystegia soldanella induce G1 and S phase arrest of the cell cycle in HepG2 cells. Int J Oncol; 2017 Feb;50(2):414-420
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This plant has long been used as an edible and medicinal herb to cure rheumatic arthritis, sore throat, dropsy, and scurvy.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2012 Sep;13(9):579-90 [22914294.001]
  • [Cites] Nat Prod Commun. 2013 Apr;8(4):431-2 [23738443.001]
  • [Cites] J Nat Prod. 2011 Nov 28;74(11):2414-9 [21992192.001]
  • [Cites] J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):83-91 [27134458.001]
  • [Cites] Mar Drugs. 2016 Feb 18;14 (2):null [26901207.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2014;62(1):97-105 [24390499.001]
  • [Cites] Curr Med Chem. 2003 Dec;10(23):2549-58 [14529470.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):419-24 [15452455.001]
  • [Cites] Med Res Rev. 2016 Jan;36(1):169-89 [26332654.001]
  • [Cites] Mar Drugs. 2015 Sep 30;13(10):6152-209 [26437418.001]
  • [Cites] Food Chem Toxicol. 2010 Feb;48(2):722-8 [20026161.001]
  • [Cites] Nat Prod Res. 2013;27(21):1965-70 [23706100.001]
  • [Cites] Eur J Pharmacol. 2007 Dec 8;576(1-3):26-33 [17716651.001]
  • [Cites] PLoS One. 2016 Apr 11;11(4):e0151502 [27064569.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31 [18495520.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2011;59(9):1163-8 [21881263.001]
  • [Cites] Nutr Cancer. 2013;65(2):255-62 [23441613.001]
  • [Cites] Bioorg Med Chem. 2015 Jun 15;23 (12 ):2810-8 [25703307.001]
  • [Cites] Nat Prod Bioprospect. 2014 Jun;4(3):189-96 [24955301.001]
  • [Cites] Nat Prod Commun. 2014 Nov;9(11):1585-8 [25532287.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2014;62(8):839-44 [25087638.001]
  • [Cites] Phytochemistry. 2001 Jul;57(5):721-6 [11397439.001]
  • [Cites] FEBS Open Bio. 2016 Oct 24;6(11):1093-1101 [27833850.001]
  • [Cites] J Cancer Prev. 2015 Dec;20(4):241-9 [26734586.001]
  • [Cites] Bioorg Med Chem Lett. 2012 Jul 1;22(13):4318-22 [22652051.001]
  • [Cites] Asian Pac J Cancer Prev. 2012;13(12):6073-6 [23464406.001]
  • [Cites] Plant Cell Environ. 2002 Feb;25(2):275-294 [11841670.001]
  • [Cites] Yakugaku Zasshi. 1977 Dec;97(12):1369-71 [609052.001]
  • [Cites] CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 [25559415.001]
  • [Cites] J Asian Nat Prod Res. 2014;16(4):370-5 [24597719.001]
  • [Cites] Cell Cycle. 2010 Feb 15;9(4):689-99 [20107323.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2015;63(8):641-8 [26235171.001]
  • [Cites] Cancer Biol Ther. 2012 May;13(7):451-7 [22361734.001]
  • [Cites] Nat Prod Commun. 2014 Jul;9(7):921-4 [25230493.001]
  • [Cites] Nat Prod Res. 2014;28(13):960-6 [24945315.001]
  • [Cites] Fitoterapia. 2000 Aug;71(4):353-9 [10925003.001]
  • [Cites] Nat Prod Commun. 2011 Dec;6(12):1889-92 [22312731.001]
  • [Cites] Br J Pharmacol. 2014 Apr;171(7):1655-67 [24328908.001]
  • [Cites] Mar Drugs. 2014 Jul 07;12(7):4069-85 [25003791.001]
  • [Cites] C R Biol. 2008 Nov;331(11):865-73 [18940702.001]
  • [Cites] Chin Med J (Engl). 1999 Oct;112(10):887-91 [11717970.001]
  • [Cites] J Cell Biochem. 2008 May 1;104(1):339-56 [18092339.001]
  • (PMID = 28101580.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


3. Uroos M, Abbas Z, Sattar S, Umer N, Shabbir A, Shafiq-Ur-Rehman, Sharif A: <i>Nyctanthes arbor-tristis</i> Ameliorated FCA-Induced Experimental Arthritis: A Comparative Study among Different Extracts. Evid Based Complement Alternat Med; 2017;2017:4634853

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <i>Nyctanthes arbor-tristis</i> Ameliorated FCA-Induced Experimental Arthritis: A Comparative Study among Different Extracts.
  • <i>Nyctanthes arbor-tristis</i> (NAT) is commonly used traditionally for the treatment of rheumatism and inflammatory diseases.
  • NAT extracts suppressed arthritic scoring, paw edema, infiltration of inflammatory cells, pannus formation, and bone erosion.
  • Current study showed that <i>Nyctanthes arbor-tristis</i> ameliorated experimental rheumatoid arthritis and ethyl acetate extract possessed the highest inhibitory activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2016 May;15(5):305-6 [27080040.001]
  • [Cites] F1000Prime Rep. 2014 May 06;6:31 [24860653.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2014 Sep;115(3):244-56 [25275147.001]
  • [Cites] Lancet. 2010 Sep 25;376(9746):1094-108 [20870100.001]
  • [Cites] J Postgrad Med. 2004 Jan-Mar;50(1):60-1 [15048003.001]
  • [Cites] Clin Med Insights Arthritis Musculoskelet Disord. 2013 Aug 08;6:35-43 [23997576.001]
  • [Cites] Int Immunopharmacol. 2015 May;26(1):265-71 [25863235.001]
  • [Cites] Evid Based Complement Alternat Med. 2011;2011:785245 [19770265.001]
  • [Cites] BMC Complement Altern Med. 2010 Oct 13;10:56 [20939932.001]
  • [Cites] Fundam Clin Pharmacol. 2014 Aug;28(4):455-64 [24102680.001]
  • [Cites] Inflammation. 2016 Dec;39(6):1918-1929 [27561645.001]
  • [Cites] Arthritis Res Ther. 2013;15 Suppl 3:S2 [24267197.001]
  • [Cites] J Ethnopharmacol. 2013 Apr 19;146(3):645-58 [23376280.001]
  • [Cites] Inflamm Allergy Drug Targets. 2009 Mar;8(1):28-39 [19275691.001]
  • [Cites] J Agric Food Chem. 2007 Oct 3;55(20):8040-6 [17867636.001]
  • [Cites] Eur J Pharmacol. 2014 Sep 5;738:263-72 [24943733.001]
  • [Cites] J Biol Chem. 2011 Sep 16;286(37):32866-74 [21799001.001]
  • [Cites] Nepal Med Coll J. 2011 Jun;13(2):74-6 [22364085.001]
  • [Cites] Evid Based Complement Alternat Med. 2014;2014:269431 [25614748.001]
  • [Cites] Front Immunol. 2015 Jul 27;6:384 [26284069.001]
  • [Cites] Biomed Res Int. 2015 ;2015 :786104 [26000303.001]
  • [Cites] Curr Med Chem. 2012;19(14):2104-27 [22414102.001]
  • [Cites] Evid Based Complement Alternat Med. 2011;2011:986797 [21234398.001]
  • [Cites] Biomed Res Int. 2013;2013:826295 [23984409.001]
  • [Cites] N Engl J Med. 2011 Dec 8;365(23):2205-19 [22150039.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):229 [19519924.001]
  • [Cites] Evid Based Complement Alternat Med. 2016;2016:1230294 [27382402.001]
  • [Cites] Evid Based Complement Alternat Med. 2016;2016:8292486 [27525026.001]
  • (PMID = 28676830.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Nguyen TD, Thuong PT, Hwang IH, Hoang TK, Nguyen MK, Nguyen HA, Na M: Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content. BMC Complement Altern Med; 2017 Apr 04;17(1):191
Hazardous Substances Data Bank. CARRAGEENAN GUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content.
  • BACKGROUND: The medicinal plant Siegesbeckia orientalis L. has been commonly used for the treatment of acute arthritis, rheumatism, and gout in Vietnam.
  • Anti-hyperuricemic and anti-inflammatory effects were evaluated and observed for the crude ethanol extract (CEE) of S. orientalis.
  • Anti-inflammatory activities of the BuOH fr. were also evaluated in vivo using carrageenan-induced paw edema and urate-induced synovitis in rats.
  • CONCLUSIONS: This study suggested that anti-hyperuricemic and anti-inflammatory mechanism of S. orientalis is related to XO inhibitory effect of the phenolic components.
  • Our findings support the use of this plant as the treatment of gout and other inflammatory diseases.
  • [MeSH-major] Analgesics / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Asteraceae / chemistry. Hyperuricemia / drug therapy. Phytotherapy. Plant Extracts / therapeutic use
  • [MeSH-minor] Animals. Carrageenan. Disease Models, Animal. Liver / drug effects. Liver / enzymology. Male. Phenols / chemistry. Phenols / isolation & purification. Plants, Medicinal. Rats. Rats, Wistar. Uric Acid / blood. Vietnam. Xanthine Oxidase / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Feb 15;334(7):445-51 [8552148.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2005 Feb;53(2):232-4 [15684525.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jan;304(1):56-62 [12490575.001]
  • [Cites] J Ethnopharmacol. 2006 Dec 6;108(3):462-70 [16876348.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1551-6 [17666819.001]
  • [Cites] Acta Physiol Scand Suppl. 1986;554:221-33 [3469880.001]
  • [Cites] Pharmacol Res Commun. 1975 Apr;7(2):117-24 [1144488.001]
  • [Cites] Br J Pharmacol. 1997 Aug;121(8):1619-26 [9283695.001]
  • [Cites] Int J Food Sci Nutr. 2016;67(3):283-7 [26940252.001]
  • [Cites] Am J Manag Care. 2005 Nov;11(15 Suppl):S451-8; quiz S465-8 [16300459.001]
  • [Cites] J Ethnopharmacol. 2004 Jul;93(1):133-40 [15182918.001]
  • [Cites] Proc Soc Exp Biol Med. 1962 Dec;111:544-7 [14001233.001]
  • [Cites] N Engl J Med. 2011 Feb 3;364(5):443-52 [21288096.001]
  • [Cites] Food Chem Toxicol. 2011 Sep;49(9):1943-7 [21600261.001]
  • [Cites] J Nat Prod. 2009 Nov;72(11):2005-8 [19813758.001]
  • [Cites] J Nat Prod. 2014 Jul 25;77(7):1693-9 [25060641.001]
  • [Cites] J Nat Prod. 2004 Sep;67(9):1517-21 [15387652.001]
  • [Cites] Biomed Res Int. 2014;2014:329712 [25328884.001]
  • [Cites] Biol Pharm Bull. 2004 Sep;27(9):1414-21 [15340229.001]
  • [Cites] Free Radic Biol Med. 2014 Apr;69:300-7 [24503177.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Pain. 2000 Dec 15;89(1):65-74 [11113294.001]
  • [Cites] Arthritis Res Ther. 2010;12 (2):206 [20441605.001]
  • [Cites] Clin Chem. 1971 Mar;17(3):158-60 [5543187.001]
  • [Cites] Biol Pharm Bull. 2005 Dec;28(12):2231-4 [16327155.001]
  • [Cites] Phytomedicine. 2007 Dec;14(12):825-9 [17350237.001]
  • [Cites] J Ethnopharmacol. 2011 Oct 11;137(3):1089-94 [21798328.001]
  • [Cites] Pharmazie. 2014 Apr;69(4):243-56 [24791587.001]
  • (PMID = 28376775.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Phenols; 0 / Plant Extracts; 268B43MJ25 / Uric Acid; 9000-07-1 / Carrageenan; EC 1.17.3.2 / Xanthine Oxidase
  • [Keywords] NOTNLM ; Analgesic activity / Anti-hyperuricemic activity / Anti-inflammatory activity / Caffeic acid analogues / Flavonones / Siegesbeckia orientalis / Xanthine oxidase
  •  go-up   go-down


5. Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes REM, Trouw LA, Huizinga TWJ, Berenbaum F, Morel J, Rantapää-Dahlqvist S, van der Helm-van Mil AHM: The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Res Ther; 2017 May 31;19(1):115
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
  • BACKGROUND: Rheumatoid arthritis (RA) consists of two syndromes, one autoantibody-positive and one autoantibody-negative.
  • Further biologic studies are needed to characterize the pathogenesis of ACPA-negative polyarthritis at older age and to promote personalized treatment decisions in ACPA-negative patients in daily practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2016 Apr;76(4):716-720 [28283528.001]
  • [Cites] Ann Rheum Dis. 2006 Mar;65(3):366-71 [16014670.001]
  • [Cites] Rheumatology (Oxford). 2004 May;43(5):655-7 [14970400.001]
  • [Cites] Rheumatol Int. 2013 Nov;33(11):2881-4 [22955876.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3799-808 [17133560.001]
  • [Cites] Joint Bone Spine. 2015 Jan;82(1):13-7 [25238951.001]
  • [Cites] Joint Bone Spine. 2016 Oct;83(5):511-5 [26992954.001]
  • [Cites] Ann Rheum Dis. 2011 Aug;70(8):1461-4 [21666230.001]
  • [Cites] Ann Rheum Dis. 2002 Dec;61(12):1055-9 [12429534.001]
  • [Cites] Ann Rheum Dis. 2011 Feb;70(2):259-65 [21156761.001]
  • [Cites] Semin Arthritis Rheum. 2012 Aug;42(1):23-31 [22465003.001]
  • [Cites] Ann Rheum Dis. 2017 Jan;76(1):112-118 [27117699.001]
  • [Cites] Rheumatol Int. 2003 Mar;23(2):70-4 [12634939.001]
  • [Cites] Arthritis Res Ther. 2015 Aug 24;17 :222 [26299443.001]
  • [Cites] Rheumatol Int. 2013 Apr;33(4):939-42 [22829412.001]
  • [Cites] Ann Rheum Dis. 2010 Jun;69(6):1110-6 [20439289.001]
  • [Cites] Ann Rheum Dis. 2011 Feb;70(2):373-9 [21068094.001]
  • [Cites] Arthritis Rheum. 1985 Sep;28(9):987-94 [4038365.001]
  • [Cites] BMC Med. 2013 Apr 04;11:94 [23556986.001]
  • [Cites] Arch Gerontol Geriatr. 2006 Mar-Apr;42(2):225-31 [16191448.001]
  • [Cites] J Rheumatol. 1997 Jan;24(1):20-7 [9002006.001]
  • [Cites] Ann Rheum Dis. 1959 Mar;18(1):49-51; French transl 51-2; Spanish transl 52-3 [13650459.001]
  • [Cites] Gerontology. 2009;55(3):250-8 [18849599.001]
  • [Cites] Rheumatology (Oxford). 2011 Jan;50(1):93-100 [20639266.001]
  • [Cites] Arthritis Res Ther. 2014 Apr 14;16(2):R94 [24731866.001]
  • [Cites] Ann Rheum Dis. 2017 Jan 2;:null [28043998.001]
  • [Cites] Vaccine. 2005 May 9;23(25):3232-5 [15837226.001]
  • [Cites] Rheum Dis Clin North Am. 2012 May;38(2):405-26 [22819092.001]
  • [Cites] Ann Rheum Dis. 2012 Oct;71(10 ):1651-7 [22440823.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Curr Opin Rheumatol. 2015 May;27(3):262-7 [25760280.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):38-46 [16385494.001]
  • [Cites] Vaccine. 2000 Feb 25;18(16):1624-8 [10689139.001]
  • [Cites] Arthritis Rheum. 2013 Jul;65(7):1684-93 [23529819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17372-7 [21987802.001]
  • [Cites] Clin Rheumatol. 2005 Sep;24(5):485-9 [15750680.001]
  • [Cites] Rheum Dis Clin North Am. 2000 Aug;26(3):517-26 [10989510.001]
  • [Cites] Rheumatology (Oxford). 2000 Sep;39(9):1031-6 [10986311.001]
  • [Cites] J Rheumatol. 2000 Jan;27(1):47-57 [10648017.001]
  • [Cites] Semin Arthritis Rheum. 1994 Jun;23(6):367-78 [7939723.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Dec;66(12):1818-27 [24942650.001]
  • [Cites] Curr Aging Sci. 2015;8(2):131-46 [26212057.001]
  • [Cites] Curr Opin Rheumatol. 2014 Jan;26(1):93-100 [24296720.001]
  • (PMID = 28569212.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ACPA characteristics / Age / Autoantibodies / Rheumatoid arthritis
  •  go-up   go-down


6. Hirota T, Tsuboi H, Takahashi H, Asashima H, Ohta M, Wakasa Y, Matsumoto I, Takaiwa F, Sumida T: Suppression of GPI-induced arthritis by oral administration of transgenic rice seeds expressing altered peptide ligands. Nihon Rinsho Meneki Gakkai Kaishi; 2017;40(1):28-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of GPI-induced arthritis by oral administration of transgenic rice seeds expressing altered peptide ligands.
  • OBJECTIVE: To investigate the effects and mechanisms of transgenic rice seeds expressing the altered peptide ligand (APL) of human glucose-6-phosphate-isomerase (hGPI<sub>325-339</sub>) in mice model of GPI induced arthritis (GIA).
  • The severity of arthritis and titers of serum anti-GPI antibodies were evaluated.
  • RESULTS: Prophylactic treatment of GIA mice with APL12 transgenic rice seeds (APL12-TG) significantly improved the severity of arthritis, histopathological arthritis scores, and decreased titers of serum anti-GPI antibodies, BAFF mRNA in iLN cells, IL-17 production in splenocytes and iLN cells compared with non-transgenic rice-treated mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28539551.001).
  • [ISSN] 1349-7413
  • [Journal-full-title] Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology
  • [ISO-abbreviation] Nihon Rinsho Meneki Gakkai Kaishi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; altered peptide ligand (APL) / glucose-6-phosphate isomerase (GPI) / transgenic rice seed
  •  go-up   go-down


7. Gao S, Wang Q, Tian XH, Li HL, Shen YH, Xu XK, Wu GZ, Hu ZL, Zhang WD: Total sesquiterpene lactones prepared from Inula helenium L. has potentials in prevention and therapy of rheumatoid arthritis. J Ethnopharmacol; 2017 Jan 20;196:39-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total sesquiterpene lactones prepared from Inula helenium L. has potentials in prevention and therapy of rheumatoid arthritis.
  • BACKGROUNDS: Inula helenium L. is an herb with anti-inflammatory properties.
  • However, the anti-inflammatory effects of SL-containing extracts of I. helenium have not been explored.
  • Here we prepared total SLs from I. helenium (TSL-IHL), analyzed its chemical constituents, and performed cellular and animal studies to evaluate its anti-inflammatory activities.
  • Its in vitro effects on the activation of signaling pathways and expression of inflammatory genes were examined by western blotting and quantitative real-time PCR, respectively, and compared with those of AL and IAL.
  • Its in vivo anti-inflammatory effects were evaluated in adjuvant- and collagen-induced arthritis rat models.
  • Oral administration of TSL-IHL at 12.5-50mg/kg could dose-dependently alleviate the arthritic severity and paw swelling in either developing or developed phases of arthritis of rats induced by adjuvant or collagen CONCLUSIONS: These results indicated potentials of TSL-IHL in prevention and therapy of rheumatoid arthritis.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Arthritis, Experimental / drug therapy. Arthritis, Rheumatoid / drug therapy. Inula. Lactones / therapeutic use. Sesquiterpenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 27988396.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cytokines; 0 / Lactones; 0 / NF-kappa B; 0 / Sesquiterpenes; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Keywords] NOTNLM ; Anti-inflammatory / Inula helenium L. / Rheumatoid arthritis / Total sesquiterpene lactones
  •  go-up   go-down


8. Calip GS, Adimadhyam S, Xing S, Rincon JC, Lee WJ, Anguiano RH: Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum; 2017 Mar 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We estimated medication adherence/persistence over time following initiation in young adult and older adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28410817.001).
  • [ISSN] 1532-866X
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Ankylosing spondylitis / Medication adherence / Persistence / Psoriatic arthritis / Rheumatoid arthritis / TNF inhibitors
  •  go-up   go-down


9. Tanwar A, Chawla R, Ansari MM, Neha, Thakur P, Chakotiya AS, Goel R, Ojha H, Asif M, Basu M, Arora R, Khan HA: In vivo anti-arthritic efficacy of Camellia sinensis (L.) in collagen induced arthritis model. Biomed Pharmacother; 2017 Mar;87:92-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo anti-arthritic efficacy of Camellia sinensis (L.) in collagen induced arthritis model.
  • BACKGROUND: Rheumatoid arthritis (RA), an autoimmune inflammatory disorder with synovial hyperplasia, destruction of cartilage, bone damage is often associated with risk of infections.
  • Four different oral doses (50, 100, 200, 400mg/kg/body wt.) of aquo-alcoholic extract were evaluated for anti-edematogenic effect in collagen induced arthritis model.
  • The selected anti-arthritic doses of Cs were evaluated for the oxidative stress markers like Glutathione [5-5'dithio-bis-2-nitrobenzoicacid (DTNB)], Superoxide dismutase [Epinephrine], Catalase [Hydrogen peroxide], Lipid peroxidation [Thiobarbituric acid reactive substance (TBARS)], Nitric oxide [Griess reagents:Nitrobluetetrazolium], Articular elastase [N-methoxysuccinyl-Ala-Ala-Pro- Val p-nitroanilide] in joints followed by haematological evaluation including RBC, WBC, Haemoglobin, platelets and haematocrit.
  • The confirmatory analysis utilizing radiological and histological assessment showed alleviation of joint deformity, tissue swelling, pannus formation and neutrophils infiltration in treatment group as compared to collagen induced arthritis.
  • CONCLUSION: The analysis showed that Cs can play an effective role in reduction of oxidative stress by modulating levels of antioxidants, reducing levels of free radicals while restoring normal haematopoietic cascade as observed in collagen induced arthritis model.
  • Thus, the cumulative dose impact of 400mg/kg body wt., over a period of 14days also found extremely effective in terms of safeguarding their structural conformity against such auto-immune disorder.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Experimental / drug therapy. Arthritis, Experimental / pathology. Camellia sinensis. Plant Extracts / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier Masson SAS. All rights reserved.
  • (PMID = 28049097.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Plant Extracts
  • [Keywords] NOTNLM ; Anti-inflammatory / Aquo alcoholic extract / Camellia sinensis / Collagen induced arthritis / Oxidative stress
  •  go-up   go-down


10. Kerr GS, Swearingen C, Mikuls TR, Yazici Y: Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems. J Clin Rheumatol; 2017 Jan;23(1):12-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems.
  • BACKGROUND: In the United States, there is racial/ethnic disparity in the care of rheumatoid arthritis (RA), yet there are limited data regarding the impact of varied health care systems on treatment outcomes.
  • OBJECTIVE: The aim fo this study was to compare the frequencies of use of disease-modifying antirheumatic drugs and biologic agents in racial minorities with RA in a single-payer and variable-access health systems.
  • METHODS: Rheumatoid arthritis disease status was examined in the Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) and Veterans Affairs Rheumatoid Arthritis Registry (VARA); frequencies of prednisone and disease-modifying antirheumatic drugs and biologic agent use at enrollment were documented.
  • Routine Assessment of Patient Index Data 3 and Disease Activity Score in 28 Joints scores were equivalent (cohort, racial subsets), as was biologic agent use (26% vs. 28%) between whites and nonwhites.
  • Disease-modifying antirheumatic drug use was greater in EMRAC nonwhites compared with their white counterparts, but similar to all VARA patients (33% vs. 22% [P < 0.001], 36%, 39%, respectively).
  • Younger age, advanced education, longstanding disease, and severe disease were associated with biologic agent use.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid. Biological Products / therapeutic use. Health Equity. Minority Health

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28002151.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Biological Products
  •  go-up   go-down






Advertisement